HighTower Advisors
CGTX icon

HighTower Advisors’s Cognition Therapeutics CGTX Stock Holding History

HighTower Advisors’s Portfolio CGTX Stock Details CGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.2K Hold
24,000
– – ﹤0.01% 3764
2025
Q4 		$32.4K Sell
24,000
-500
-2% -$812 ﹤0.01% 3594
2025
Q3 		$33.1K Buy
24,500
+7,500
+44% +$10.2K ﹤0.01% 3642
2025
Q2 		$5.27K Sell
17,000
-7,462
-31% -$2.52K ﹤0.01% 3673
2025
Q1 		$10.3K Buy
24,462
+5,000
+26% +$2.94K ﹤0.01% 3556
2024
Q4 		$13.6K Sell
19,462
-3,500
-15% -$1.73K ﹤0.01% 3569
2024
Q3 		$11K Hold
22,962
– – ﹤0.01% 3544
2024
Q2 		$38K Hold
22,962
– – ﹤0.01% 3335
2024
Q1 		$41K Sell
22,962
-10,000
-30% -$20.6K ﹤0.01% 3281
2023
Q4 		$61K Hold
32,962
– – ﹤0.01% 3270
2023
Q3 		$47K Buy
32,962
+6,401
+24% +$10K ﹤0.01% 3238
2023
Q2 		$48K Sell
26,561
-2,000
-7% -$4.23K ﹤0.01% 3167
2023
Q1 		$58K Buy
+28,561
New +$54.4K ﹤0.01% 3029

Other funds holding CGTX

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

HighTower Advisors's CGTX Position: Q1 2026 in Review

HighTower Advisors held its Cognition Therapeutics (CGTX) position steady in Q1 2026 at 24,000 shares worth $18.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3764.

HighTower Advisors first reported a position in CGTX in Q1 2023 and has held it in 13 quarters since. The position peaked at $61K in Q4 2023. 75 funds tracked by Wall St. Rank hold CGTX as of Q1 2026.

  • HighTower Advisors held 24,000 shares of Cognition Therapeutics worth $18.2K as of Q1 2026.
  • HighTower Advisors left its Cognition Therapeutics share count unchanged in Q1 2026.
  • Cognition Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3764 holding.
  • HighTower Advisors first reported a position in Cognition Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • HighTower Advisors's Cognition Therapeutics position peaked at $61K in Q4 2023.
  • 75 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.